<DOC>
	<DOCNO>NCT01550510</DOCNO>
	<brief_summary>This protocol phase I/II , study ascorbic acid ( AA ) infusion combine treatment irinotecan versus treatment irinotecan alone patient recurrent advanced colorectal cancer fail least one treatment regimen 5-FU base therapy . This study conduct amendment Investigational New Drug # 77486 .</brief_summary>
	<brief_title>Research Study IV Vitamin C Combination With Irinotecan v Irinotecan Alone Advanced Colorectal CA</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Antineoplastic Agents , Phytogenic</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Age &gt; 18 year Metastatic colorectal carcinoma ( stage IV disease ) . Patients must progress one prior chemotherapy treatment regimens include least one trial 5FU/oxaliplatin base therapy ( FOLFOX ) combination bevacizumab . Patients must standard chemotherapy within least 2 week begin ascorbic acid treatment provide recovered toxicity experience . G6PD status &gt; low limit normal Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . Laboratory baseline evaluation inclusion study : creatinine ≤1.5X upper limit ( creatinine elevate , ≤1.5X ULN , 24 hour creatinine clearance obtain ) ; transaminase ( AST/ALT ) ≤2.0X upper limit normal ; bilirubin level ≥ 2 mg/dL ; ANC ≥1,500/mm3 ; Hemoglobin &gt; 8g/dL ; platelet ≥ 100,000/mm3 ; Women childbearing potential confirm negative pregnancy test must practice effective contraception study . Willing able provide inform consent participate study procedure . Patients evidence significant current psychiatric disorder would prevent completion study determine PI allow participate . Comorbid medical condition would affect survival tolerance determine PI . This include patient fully recovered toxicity associate prior therapy . It also include subject , determine PI , risk experience fluid overload ( i.e. , congestive heart failure ) . Patients currently abuse alcohol drug . Patients know glomerular filtration rate &lt; 60ml/min nephrotic range proteinuria . Pregnant lactate woman Enrollment active clinical trial/ experimental therapy IND study within prior 30 day . Contraindication CT PET/CT per PI . Patients strong inducer CYP3A4 include limited : Aminoglutethimide , Bexarotene , Bosentan , Carbamazepine , Dexamethasone , Efavirenz , Fosphenytoin , Griseofulvin , Modafinil , Nafcillin , Nevirapine , Oxcarbazepine , Phenobarbital , Phenytoin , Primidone , Rifabutin , Rifampin , Rifapentine , St. John 's wort .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Stage IV Colorectal cancer</keyword>
	<keyword>Colorectal Neoplasms</keyword>
	<keyword>Intestinal Neoplasms</keyword>
	<keyword>Gastrointestinal Neoplasms</keyword>
	<keyword>Digestive System Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Colonic Diseases</keyword>
	<keyword>Intestinal Diseases</keyword>
	<keyword>Rectal Diseases</keyword>
	<keyword>Ascorbic Acid</keyword>
	<keyword>Vitamins</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Integrative Medicine</keyword>
	<keyword>Complementary Medicine</keyword>
	<keyword>Alternative Medicine Antioxidants</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Protective Agents</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Micronutrients</keyword>
	<keyword>Growth Substances</keyword>
	<keyword>Antineoplastic Agents , Phytogenic</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Radiation-Sensitizing Agents</keyword>
	<keyword>Topoisomerase I Inhibitors</keyword>
	<keyword>Topoisomerase Inhibitors</keyword>
	<keyword>Enzyme Inhibitors</keyword>
</DOC>